| Literature DB >> 34093698 |
Hock Ing Chiu1, Che Nurul Azieyan Che Mood1, Nur Nadhirah Mohamad Zain1, Muggundha Raoov Ramachandran2, Noorfatimah Yahaya1, Nik Nur Syazni Nik Mohamed Kamal1, Wai Hau Tung3, Yoke Keong Yong4, Chee Keong Lee5, Vuanghao Lim1.
Abstract
Silver nanoparticles (AgNPs) previously synthesised using leaf (AgNP-L) and stem (AgNP-S) extracts of Clinacanthus nutans (C. nutans) were tested to evaluate antimicrobial, antioxidant, and cytotoxicity activities. The AgNPs showed good inhibition against bacteria, but not fungi. The inhibition results showed the highest activity against Staphylococcus aureus (S. aureus) with 11.35 mm (AgNP-L) and 11.52 mm (AgNP-S), while the lowest inhibition was against Escherichia coli (E. coli) with 9.22 mm (AgNP-L) and 9.25 mm (AgNP-S) in the disc diffusion method. The same trend of results was noted in the well diffusion method. The IC50 of AgNP-L and AgNP-S in 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assays was 417.05 μg/mL and 434.60 μg/mL, as well as 304.31 μg/mL and 326.83 μg/mL, respectively. Ferric reducing power (FRAP) assay showed that AgNP-L [872.389 μmol/L Fe(II)] and AgNP-S [612.770 μmol/L Fe(II)] exhibited significantly (p < 0.05) greater antioxidant activities than leaf extract (CNL) [152.260 μmol/L Fe(II)] and stem extract (CNS) [110.445 μmol/L Fe(II)] of C. nutans. The AgNPs were also proven to possess cytotoxic effects on the breast (MCF-7), cervical (HeLa), and colon (HT-29) cancer cells in a dose-dependent manner. AgNP-S and AgNP-L showed significantly (p < 0.05) higher cytotoxicity against MCF-7 (117.43 μg/mL) and HT-29 (78.47 μg/mL), respectively. In conclusion, the biosynthesised AgNPs from aqueous extract leaves and stem of C. nutans have demonstrated promising potential towards antioxidant, antimicrobial, and cytotoxicity activities.Entities:
Year: 2021 PMID: 34093698 PMCID: PMC8140852 DOI: 10.1155/2021/9920890
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Inhibition zones (mm) of the biosynthesised silver nanoparticles against microorganisms using the disc diffusion method (mean ± SD, n = 3); mean values are significantly different (p < 0.05) between tested samples in each particular bacterium/fungus with different lower case superscript letters a, b, c, and d.
| Samples | Inhibition zone (mm) | ||||||
|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | Fungi | |||||
| SA | SE | SP | EC | PA | CA | CG | |
| CNL | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| CNS | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| AgNP-L | 11.350 ± 0.243b | 11.597 ± 0.311b | 10.260 ± 0.125b | 9.220 ± 0.433b | 10.073 ± 0.280b | 0.000a | 0.000a |
| AgNP-S | 11.517 ± 0.519b | 10.153 ± 0.232c | 10.493 ± 0.345b | 9.247 ± 0.081b | 10.000 ± 0.305b | 0.000b | 0.000a |
| C-AgNP | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000b | 0.000a |
| dH2O | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000b | 0.000a |
| Gentamycin | 21.957 ± 0.486c | 25.543 ± 0.440d | 22.967 ± 0.799c | 21.840 ± 0.155c | 17.530 ± 0.521c | ND | ND |
| Nystatin | ND | ND | ND | ND | ND | 17.367 ± 0.136c | 21.200 ± 0.200b |
ND = not determined.
Inhibition zones (mm) of the biosynthesised silver nanoparticles against tested microorganisms using the well diffusion method (mean ± SD, n = 3); mean values are significantly different (p < 0.05) between tested samples in each particular bacterium/fungus with different lower case superscript letters a, b, c, and d.
| Samples | Zone of inhibition (mm) | ||||||
|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | Fungi | |||||
| SA | SE | SP | EC | PA | CA | CG | |
| CNL | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| CNS | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| AgNaP-L | 18.290 ± 0.303b | 16.987 ± 0.652b | 13.913 ± 0.311b | 12.830 ± 0.607b | 14.160 ± 0.436b | 0.000a | 0.000a |
| AgNaP-S | 17.237 ± 0.123c | 17.000 ± 0.146b | 13.730 ± 0.191b | 13.413 ± 4.500b | 14.140 ± 4.500b | 0.000a | 0.000a |
| C-AgNaPs | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| Gentamycin | 27.81 ± 0.206d | 31.84 ± 0.138c | 26.42 ± 0.678c | 24.45 ± 0.116c | 26.78 ± 0.102c | ND | ND |
| dH2O | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| Nystatin | ND | ND | ND | ND | ND | 26.267 ± 4.500b | 31.285 ± 5.511b |
ND = not determined.
MIC and MBC of tested samples against microorganisms.
| Samples | MIC ( | MBC ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SA | SE | SP | PA | EC | SA | SE | SP | PA | EC | |
| AgNP-L | 250 | 250 | 250 | 250 | 125 | 250 | 250 | 250 | 250 | 125 |
| AgNP-S | 250 | 250 | 250 | 125 | 125 | 250 | 250 | 250 | 125 | 125 |
| Gentamicin | 31.25 | 62.5 | 31.25 | 62.5 | 125 | 31.25 | 31.25 | 31.25 | 62.5 | 125 |
Figure 1(a) DPPH, (b) ABTS, and (c) FRAP assays. Samples with different lower case superscript letters differ significantly (p < 0.05) between them (mean ± SD, n = 3).
Figure 2Cell viability after 72 h at different concentrations (12.5–200 μg/mL) on (a) MCF-7, (b) HT-29, and (c) HeLa. The symbol (p < 0.05) represents the significant difference between the sample and control (untreated cells) (mean ± SD, n = 3).